Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 409Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 82Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 54Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Neoplasm Metastasis 44Carcinoma, Non-Small-Cell Lung 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Vaginal Neoplasms 28Prostatic Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Urinary Bladder Neoplasms 21Small Cell Lung Carcinoma 21

Interventions

TIC10 compound 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Cancer Recurrent × Gynecologic × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Jazz Pharmaceuticals

Phase 2 Terminated
27 enrolled 11 charts
Gynecologic

Endometrial Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡